Back To Top
Cell & Gene Therapy
The demand for personalized therapies is transforming the industry.

The demand for personalized therapies is transforming the industry.

The demand for personalized therapies is transforming how biotech companies are mapping the journey from research to commercial manufacturing. Growing requirements demand greater visibility of the manufacturing process, including data collection and analysis. Regulations like 21 CFR Part 11 have created a need for better systems with better system management, seamless digital data integration, and precision quality controls.

Precisely maintain the chain of identity (COI) for each patient’s batch.

In cell and gene therapy processes, manufacturers must precisely maintain the chain of identity (COI) for each patient’s batch, eliminate manual errors, and manage regulatory compliance.

Together, Control Associates and Emerson have the industry expertise and experience to solve these critical challenges through implementing advanced software technologies like our Syncade manufacturing execution system (MES) that provides the accuracy, flexibility, and manufacturing stability to help ensure that right first time production is achieved every time.

With Syncade MES, manufacturers are able to streamline the entire cell and gene therapy manufacturing process by creating an electronic chain of identity, automating manual processes for improved quality, and creating paperless batch records for accuracy and time savings.

Get in touch with an expert in this industry or send us a note about your project’s specific needs.

TALK TO ONE OF OUR EXPERTS IN THIS FIELD
(201) 934-9200
+